Weight-loss drugmaker Novo Nordisk slims sales forecast

Novo Nordisk blamed its little income forecast connected contention from copycat versions of its anti-obesity drugs successful the United States. Photo: Armend NIMANI / AFP/File
Source: AFP

Don't miss out! Get your regular dose of sports quality consecutive to your phone. Join YEN's Sports News channel connected WhatsApp now!

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, chopped its yearly income forecast connected Wednesday, citing a diminution successful its US marketplace share.

Novo Nordisk blamed the revised outlook connected contention from copycat versions of its fashionable GLP-1 injections made successful US pharmacies -- a signifier known arsenic compounding.

The institution said it present expects income maturation of 13 to 21 percent successful 2025, down from a erstwhile forecast of 16 to 24 percent.

"We person reduced our full-year outlook owed to lower-than-planned branded GLP-1 penetration, which is impacted by the accelerated enlargement of compounding successful the US," Novo Nordisk main enforcement Lars Fruergaard Jorgensen said.

"We are actively focused connected preventing unlawful and unsafe compounding and connected efforts to grow diligent entree to our GLP-1 treatments," helium said successful a statement.

US pharmacies had been allowed to marque their ain mentation of Wegovy and Ozempic owed to a shortage of the drugs.

But US regulators ruled successful February that the shortage had ended and ordered pharmacies to discontinue making the compounded versions.

Novo Nordisk is besides facing contention from US rival Eli Lilly, which makes the anti-obesity injection Zepbound.

Novo Nordisk's shares tumbled past period aft Eli Lilly announced a palmy objective proceedings of diabetes and obesity attraction orforglipron.

The Danish radical besides released first-quarter results connected Wednesday showing a nett net of 29 cardinal kroner ($4.4 billion), 14 percent higher than the aforesaid play past twelvemonth and amended than expected by analysts.

Sales roseate 19 percent to 78 cardinal kroner successful the January-to-March period.

New feature: Сheck retired quality that is picked for YOU ➡️ click connected “Recommended for you” and enjoy!

Source: AFP